Bladder Cancer and Immunotherapy

October 8, 2021, 4:50 pm -
5:20 pm
Building on a history of immune response

Watch On Demand

Session Description

Bladder cancer is the sixth most common cancer in the United States and ninth most common worldwide. While the FDA approved the Bacillus Calmette-Guérin (BCG) cancer vaccine in 1990 for the treatment of superficial, non-invasive bladder cancer, oncologists today are excited about a new class of immunotherapies called immune checkpoint inhibitors. New immunotherapies have significantly reduced the risk of recurrence for bladder cancer while also increasing the percentage of patients who see a complete response post-surgery. Dr. Arjun V. Balar, director of the Genitourinary Medical Oncology Program at NYU Langone’s Perlmutter Cancer Center, discusses the potential to further improve outcomes for patients with this disease and answers questions from the audience. We will discuss how oncologists predict patient response to immunotherapies, common mutations in bladder cancer, length of treatment, and other topics. Don’t forget to submit your questions to Dr. Balar.


Arjun Balar, M.D.

NYU Langone's Perlmutter Cancer Center

Dr. Arjun Balar is the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center and is an assistant professor in the department of medicine at the NYU School of Medicine. Dr. Balar currently oversees outpatient clinical services for patients with prostate, kidney, bladder, and testicular cancers. His areas of research include bladder cancer, immunotherapy, and molecularly targeted therapy, with a specific focus on cisplatin-ineligible patients in the hopes of identifying better-tolerated and more effective therapies in advanced and invasive/high-grade urothelial cancer. Findings from Dr. Balar’s research have led to accelerated FDA approval of two drugs for advanced bladder cancer: pembrolizumab (Keytruda®) and atezolizumab (TECENTRIC®).

On-Demand Now Available

We are excited to announce that videos from our 2021 Cancer Research Institute (CRI) Virtual Immunotherapy Patient Summit are now available to view on demand.

The on-demand videos can be found on each session page from the agenda.